A new living bandage accelerates healing across multiple wound types, researchers report.
Chronic wounds remain a significant clinical challenge, in part because it is difficult to deliver sustained, localized immune signals that coordinate tissue repair.
While cytokines play a central role in regulating inflammation and healing, conventional delivery approaches are often limited by rapid degradation and poor retention at the wound site.
Researchers at Rice University with the support of the Rice Biotech Launch Pad have developed a cytokine factory patch designed to address this challenge by continuously producing and delivering therapeutic cytokines directly within the wound environment.
The approach is described in a new peer-reviewed study in Nature Biomedical Engineering.
The cytokine factory patch is a cell-based delivery platform that uses encapsulated, engineered cells as on-site “factories” to secrete cytokines, signaling proteins that regulate immune activity and tissue regeneration, over extended periods of time. By localizing cytokine production at the wound site, the system is designed to maintain therapeutic levels of these molecules where they are needed most.
The device, developed in the laboratory of Omid Veiseh, encapsulates ARPE-19 cells engineered to secrete specific cytokines, including IL-10, IL-12 and TGF-β. These cells are housed within a biocompatible matrix that allows nutrients and therapeutic proteins to pass through while shielding the cells from the host immune system.
In preclinical studies, delivery of cytokines using the patch supported accelerated wound healing in both murine and porcine excisional wound models, demonstrating the potential of sustained, localized immunomodulation to enhance natural repair processes.
“The findings show how continuous, localized cytokine delivery can support key biological pathways involved in tissue repair,” says Veiseh, professor of bioengineering at Rice and faculty director of the Rice Biotech Launch Pad.
“By maintaining a consistent presence of these signaling molecules at the wound site, we can more effectively engage the body’s natural healing response.”
At the cellular level, the engineered cells demonstrated activation of key wound-healing pathways, which was validated through RNA sequencing. Transcriptomic analysis revealed coordinated upregulation of genes associated with tissue regeneration and immune modulation, providing a mechanistic basis for the functional improvements observed.
The platform is designed to be modular, allowing the engineered cells to be adapted to produce different combinations of cytokines, growth factors or other therapeutic proteins depending on the clinical application. In addition, the system incorporates an optimized hydrogel matrix that supports integration with the wound environment and may be further adapted to work alongside bioelectronic components.
“The ability to tune both the type and timing of cytokine delivery opens the door to more precise control over the healing process,” says Christian Schreib, assistant research professor in the bioengineering department at Rice and co-author of the paper.
“Future work will focus on expanding the flexibility of the platform, including approaches such as optogenetic control to regulate cytokine secretion in real time.”
Beyond wound healing, the cytokine factory approach represents a broader framework for localized, cell-based delivery of therapeutic proteins across a range of diseases where sustained, site-specific signaling is critical.
The research was supported by the Defense Advanced Research Projects Agency.
The content in this press release is solely the responsibility of the authors and does not necessarily represent the official views of funding entities.
Source: Rice University
